{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:19:14Z","timestamp":1789820354168,"version":"4.0.1"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,11]]},"abstract":"ABSTRACT<\/jats:title>\n \n The\n in vitro<\/jats:italic>\n activities of ceftaroline-avibactam, ceftaroline, and comparative agents were determined for a collection of bacterial pathogens frequently isolated from patients seeking care at 15 Canadian hospitals from January 2010 to December 2012. In total, 9,758 isolates were tested by using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method (document M07-A9, 2012), with MICs interpreted by using CLSI breakpoints (document M100-S23, 2013). Ceftaroline-avibactam demonstrated potent activity (MIC\n 90<\/jats:sub>\n , \u22640.5 \u03bcg\/ml) against\n Escherichia coli<\/jats:named-content>\n ,\n Klebsiella pneumoniae<\/jats:named-content>\n ,\n Klebsiella oxytoca<\/jats:named-content>\n ,\n Proteus mirabilis<\/jats:named-content>\n ,\n Enterobacter cloacae<\/jats:named-content>\n ,\n Enterobacter aerogenes<\/jats:named-content>\n ,\n Serratia marcescens<\/jats:named-content>\n ,\n Morganella morganii<\/jats:named-content>\n ,\n Citrobacter freundii<\/jats:named-content>\n , and\n Haemophilus influenzae<\/jats:named-content>\n ; >99% of isolates of\n E. coli<\/jats:named-content>\n ,\n K. pneumoniae<\/jats:named-content>\n ,\n K. oxytoca<\/jats:named-content>\n ,\n P. mirabilis<\/jats:named-content>\n ,\n M. morganii<\/jats:named-content>\n ,\n C. freundii<\/jats:named-content>\n , and\n H. influenzae<\/jats:named-content>\n were susceptible to ceftaroline-avibactam according to CLSI MIC interpretative criteria for ceftaroline. Ceftaroline was less active than ceftaroline-avibactam against all species of\n Enterobacteriaceae<\/jats:named-content>\n tested, with rates of susceptibility ranging from 93.9% (\n P. mirabilis<\/jats:named-content>\n ) to 54.0% (\n S. marcescens<\/jats:named-content>\n ). All isolates of methicillin-susceptible\n Staphylococcus aureus<\/jats:named-content>\n (MIC\n 90<\/jats:sub>\n , 0.25 \u03bcg\/ml) and 99.6% of methicillin-resistant\n S. aureus<\/jats:named-content>\n isolates (MIC\n 90<\/jats:sub>\n , 1 \u03bcg\/ml) were susceptible to ceftaroline; the addition of avibactam to ceftaroline did not alter its activity against staphylococci or streptococci. All isolates of\n Streptococcus pneumoniae<\/jats:named-content>\n (MIC\n 90<\/jats:sub>\n , 0.03 \u03bcg\/ml),\n Streptococcus pyogenes<\/jats:named-content>\n (MIC\n 90<\/jats:sub>\n , \u22640.03 \u03bcg\/ml), and\n Streptococcus agalactiae<\/jats:named-content>\n (MIC\n 90<\/jats:sub>\n , 0.015 \u03bcg\/ml) tested were susceptible to ceftaroline. We conclude that combining avibactam with ceftaroline expanded its spectrum of activity to include most isolates of\n Enterobacteriaceae<\/jats:named-content>\n resistant to third-generation cephalosporins, including extended-spectrum \u03b2-lactamase (ESBL)- and AmpC-producing\n E. coli<\/jats:named-content>\n and ESBL-producing\n K. pneumoniae<\/jats:named-content>\n , while maintaining potent activity against staphylococci and streptococci.\n <\/jats:p>","DOI":"10.1128\/aac.01485-13","type":"journal-article","created":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T04:14:23Z","timestamp":1377576863000},"page":"5600-5611","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":35,"title":["In Vitro<\/i>\n Activity of Ceftaroline-Avibactam against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals from 2010 to 2012: Results from the CANWARD Surveillance Study"],"prefix":"10.1128","volume":"57","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[{"name":"Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Adam","sequence":"additional","affiliation":[{"name":"Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"Baxter","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe R. S.","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[{"name":"Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Walkty","sequence":"additional","affiliation":[{"name":"Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[{"name":"Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Zhanel","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00330-12"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01787-10"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp231"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02436-12"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01516-09"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969070-00003"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01788-09"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"GoldsteinEJCCitronDMMerriamCVTyrrellKL. 24 April 2013. Comparative in vitro activity of ceftaroline ceftaroline-avibactam and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds. Diagn. Microbiol. Infect. Dis. http:\/\/dx.doi.org\/10.1016\/j.diagmicrobio.2013.03.019.","DOI":"10.1016\/j.diagmicrobio.2013.03.019"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm150"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00817-12"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks079"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq161"},{"key":"e_1_3_2_14_2","volume-title":"Antimicrobial activity of ceftaroline-avibactam tested against clinical Enterobacteriaceae isolates carrying multiple \u03b2-lactamases from USA medical centers","author":"Sader HS","year":"2012","unstructured":"SaderHSCastanheiraMFlammRKJonesRN. 2012. Antimicrobial activity of ceftaroline-avibactam tested against clinical Enterobacteriaceae isolates carrying multiple \u03b2-lactamases from USA medical centers, abstr A660. Abstr. 112th Gen. Meet. Am. Soc. Microbiol., San Francisco, CA, 16 to 19 June 2012."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205073109"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02247-12"},{"key":"e_1_3_2_18_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standardM07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_19_2","volume-title":"Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1204-1214.2004"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01690097"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.879"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01176-07"},{"key":"e_1_3_2_24_2","first-page":"459","article-title":"Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum beta-lactamase production","volume":"173","author":"Caroff N","year":"1999","unstructured":"CaroffNEspazeEBerardIRichetHReynaudA. 1999. Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum beta-lactamase production. FEMS Microbiol. Lett. 173:459\u2013465.","journal-title":"FEMS Microbiol. Lett."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.12.6147-6149.2005"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/754249"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/11318430-000000000-00000"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01021-08"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00149-08"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3501-3512.2005"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp493"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00019-10"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00484-13"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00024-11"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05005-11"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01485-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01485-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:33:30Z","timestamp":1645482810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01485-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1128\/AAC.01485-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01485-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"2013-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}